Funding for this research was provided by:
Received: 23 January 2018
Accepted: 29 January 2018
First Online: 12 February 2018
Ethics approval and consent to participate
: The Clinical Research Ethics Board at the University of British Columbia approved this study (H15–00062). The anonymized data were provided to us through the Freedom of Information and Protection of Privacy Act (FIPPA).
: Not applicable.
: JMF has served on advisory boards for, AstraZeneca, Novartis, Pfizer, Novartis, Boehringer-Ingelheim. He has also been a member of speakers’ bureaus for, AstraZeneca, Boehringer-Ingelheim, Pfizer, and Merck. He has received research funding paid directly to the University of British Columbia from the Canadian Institutes of Health Research, AstraZeneca, Glaxo-SmithKline, Boehringer-Ingelheim, Merck, Amgen, and Genentech. JMF is a member of the Global Initiative for Asthma (GINA) Executive and Science Committee. LL has served on advisory boards from AstraZeneca, Novartis, Boehringer-Ingelheim, Teva, and Pfizer.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.